EIF4E (eukaryotic translation initiation factor 4E)

2010-05-01   Katherine LB Borden , Biljana Culjkovic-Kraljacic , Laurent Volpon 

Institute of Research in Immunology, Cancer (IRIC), Department of Pathology, Cell Biology, Universite de Montreal, Pavillion Marcelle-Coutu, Chemin Polytechnique, Montreal, QC, Canada





The EIF4E gene spans >50 kbp and contains 8 exons, one of them being alternative. It codes for the major, 4749 nucleotides long transcript variant 1, that codes 217 aa long protein. The longest transcript, variant 2 (4842 nucleotides) contains an additional in-frame exon in 3 coding region compared to variant 1 and codes for a protein (248 aa long, isoform 2) with a longer c-terminus compared to isoform 1. Transcript variant 3 is 3406 nucleotide long and uses an alternative exon for the 5UTR and 5 coding region that results in translation initiation from a distinct ATG, and an isoform 3, (237 aa) with a longer and distinct N-terminus compared to isoform 1. Transcript variants 2 and 3 are predicted from cDNA sequences, but their expression at mRNA or protein levels was not studied.


The promoter of the EIF4E gene lacks a canonical TATA box, but it contains a polypyrimidine element at position -25, named the eIF4E basal element (4EBE) that binds hnRNPK. hnRNPK interacts with TATA-binding protein and recruits it to the promoter, explaining how the 4EBE might replace the TATA box in the EIF4E promoter (Lynch et al., 2005). Mapping of the minimal EIF4E promoter was found to contain CACGTG E box repeats (positions -77 and -232) that are c-myc responsive (Jones et al., 1996; Makhlouf et al., 2001). The same elements overlap for USF binding. Later mapping studies of the 2 kb promoter found AP-1 binding elements involved in EIF4E transcriptional regulation in cardiac muscle cells (Makhlouf et al., 2001) as well as Rel, Myb, NF-kB, SP-1, NF1, STAT, AP-4, ATB and CREB consensus motifs. p53 could also be involved in the regulation of eIF4E-1 expression through its binding to c-myc, thereby preventing c-myc binding to the EIF4E promoter (Gao et al., 1998; Zhu et al., 2005).
It was shown that eIF4E mRNA contains an AU-rich elements in the 3UTR that is responsible for HuR-mediated binding and stabilization (Topisirovic et al., 2009b).


Two pseudogenes are mapped so far: EIF4EP1 (also known as EIF4EL2 and dJ1022P6.3), on chromosome 20 (location 20p13), (Entrez Gene ID: 1980), (Pelletier et al., 1991), and EIF4EP2 on chromosome 17 (17q21.32), (Entrez Gene ID: 100113387).
In the report by Gao et al. (1998), numerous intronless eIF4E pseudogenes were found, all containing premature in-frame stop codons.


Atlas Image
Ternary complex of m7GpppA-eIF4E-4EBP1 peptide. eIF4E (blue) and the 4E-BP1 peptide (green) are shown with the ribbon model. The cap-recognition mode of eIF4E is characterized by a pi-pi sandwiching of the m7G base of the cap (here m7GpppA, orange) by the Trp56 and Trp102 indole rings.


eIF4E is a 25 kD cap-binding protein, which exists both in a free form and as part of a multiprotein complex termed eIF4F. The eIF4E protein has two distinct functions. First, the eIF4E polypeptide functions in delivering cellular mRNAs to the eIF4F complex to further facilitate ribosome loading and mRNA translation. The other subunits of eIF4F complex are: eIF4A, a 50 kD polypeptide, ATP-dependent RNA helicase that facilitates melting of the mRNA secondary structure, and eIF4G, a 220 kD scaffolding protein of this complex. Second, eIF4E functions in mRNA export (see below).
The cap-bound form of eIF4E was solved by X-ray crystallography for the human and mouse eIF4E and by NMR solution structure for the yeast homolog. It was shown that each consists of eight-stranded anti-parallel beta-sheets supported by three alpha-helices forming the palm and back of a "cupped" hand (Marcotrigiano et al., 1997; Matsuo et al., 1997; Tomoo et al., 2002). Two Trp residues (Trp56 and Trp102 for human eIF4E) located within a narrow cavity inside the concave surface, hold the guanine residue of the cap-analogue through pi-pi stacking interactions (McCoy et al., 1997; Wieczorek et al., 1997). A third Trp residue (Trp166 in human eIF4E) recognizes the presence of the N7-methyl group of the cap structure. NMR structure of cap-free eIF4E (apo-eIF4E) exhibits structural differences in the cap-binding site and dorsal surface relative to cap-eIF4E. Alterations in the S4-H4 loop distal to cap binding site seems to be a key in modulating conformational changes of eIF4E upon ligand binding (Volpon et al., 2006).
Although human and S. cerevisiae eIF4E counterparts have only approximately 30% sequence identity, they are functionally conserved and mammalian eIF4Es can rescue the lethality of eIF4E gene disruption in S. cerevisiae (Altmann et al., 1989; Joshi et al., 2002). Amino acid alignments of mammalian eIF4Es with eIF4Es from plants and yeast, coupled with deletion analyses from S. cerevisiae and D. rerio, reveal that the core of eIF4E represented by ~170 amino acids (from His37 to His200 in human eIF4E) is conserved in all eukaryotes and is sufficient for cap recognition and binding to eIF4G and 4E-BPs (Vasilescu et al., 1996; Robalino et al., 2004), while N- and C-termini are considerably variable both in length and sequence (suggesting that they are dispensable for translation). It is possible that N- and C-termini may be involved in the regulation of eIF4E activity or could affect the stability of the protein (Scheper et al., 2002; Gross et al., 2003). Crystallographic studies of mouse eIF4E bound to either a fragment of eIF4G or 4E-BP1 revealed that His37, Pro38, Val69, Trp73, Leu131, Glu132 and Leu135 (of human eIF4E) interact with eIF4E-binding regions of eIF4G and 4E-BPs (Marcotrigiano et al., 1999). Residues Val69 and Trp73 are found within the phylogenetically conserved part of the consensus sequence. Substitution of Trp73 of mammalian eIF4E to non-aromatic amino acid disrupts ability of eIF4E to interact with eIF4G and 4E-BPs (Ptushkina et al., 1999). Substitution of human eIF4E Val69 for a Gly results in a variant that efficiently binds 4E-BP1, but has reduced capacity to interact with eIF4G and 4E-BP2 (Vasilescu et al., 1996; Ptushkina et al., 1999).
eIF4E undergoes regulated phosphorylation at residue Ser209 (Flynn et al., 1995; Joshi et al., 1995). Mnk1 and Mnk2 are identified as kinases that phosphorylate Ser209, and they are targets for mitogen-activated extracellular signal-regulated kinase and stress/cytokine-activated p38 mitogen-activated protein kinase pathways (Waskiewicz et al., 1997; Wang et al., 1998; Waskiewicz et al., 1999; Scheper et al., 2001). Both enzymes also associate with eIF4G in vivo (Pyronnet et al., 1999; Waskiewicz et al., 1999; Scheper et al., 2001). The structural basis is still not clear as to whether phosphorylation of Ser209 substantially changes the affinity of eIF4E for the cap structure (Minich et al., 1994; Scheper et al., 2002b).
It was shown that eIF4E could be ubiquitinated and degraded in proteasome-dependent manner (Othumpangat et al., 2005; Murata et al., 2006).
Recently, it was suggested that eIF4E could be modified by SUMO1 conjugation (Xu et al., 2010).


eIF4E is ubiquitously expressed, and its presence is essential for viability of cells or whole organisms (Altmann et al., 1987). The level of expression and phosphorylation status may vary between tissues and cellular differentiation state (Mao et al., 1992; Fahrenkrug et al., 1999; Walsh et al., 2003). It was shown that eIF4E is over-expressed in many types of cancer (see below).


eIF4E is localized both in the cytoplasm and the nucleus of the cell. Up to 68% of eIF4E is found in the nucleus of cells from a wide variety of species ranging from yeast to humans (Lejbkowicz et al., 1992; Iborra et al., 2001; Strudwick et al., 2002). Localization of eIF4E can also be dynamic (Fahrenkrug et al., 1999; Strudwick et al., 2002).


In the cytoplasm, eIF4E functions in the rate limiting step of cap-dependent translation initiation (Sonenberg et al., 1998). Here, eIF4E directly binds the 7-methyl guanosine "m7G cap" structure found on the 5 end of mRNAs, and recruits transcripts to the ribosomes thereby increasing translational efficiency (Pestova et al., 2000; von der Haar et al., 2004). In order for translation to proceed, eIF4E must associate with other factors of the eIF4F complex (eIF4G and eIF4A), as well as the other factors such as the ribosome-bound eIF3 and the poly(A)-binding protein. Once formed, the eIF4F complex is thought to scan 5-3 from the cap, unwinding any existing secondary structure within the 5UTR region to reveal the translation initiation codon and to facilitate ribosome loading on the mRNA (Gingras et al., 1999). Importantly, eIF4E effects the translation of some mRNAs, known as eIF4E sensitive, more than other transcripts. When eIF4E is overexpressed, sensitive transcripts have a higher ribosome/mRNA ratio enabling more efficient translation (without modulating mRNA levels in the cytoplasm). Notably, sensitive mRNAs have more highly structured 5UTRs versus insensitive housekeeping mRNAs such as GAPDH or actin, which contain short, unstructured 5UTRs (Rhoads et al., 1993; Sonenberg et al., 1998; De Benedetti et al., 1999). Transcripts controlled at this level often code for proteins involved in proliferation such as c-myc, Pim 1, VEGF and ODC (Rhoads et al., 1993; Kevil et al., 1996; Rousseau et al., 1996; Hoover et al., 1997).
In the nucleus, eIF4E functions in the mRNA export of a specific subset of mRNAs, which contain a discrete 50 nucleotides element in their 3UTR known as the eIF4E sensitivity element (4E-SE) (Rousseau et al., 1996; Culjkovic et al., 2005; Culjkovic et al., 2006; Culjkovic et al., 2007). Many mRNAs sensitive to eIF4E at the export level code for proteins that promote proliferation and survival (such as cyclin D1 and ODC mRNAs). Unlike bulk mRNA export which is TAP/NXF1 dependent, eIF4E dependent mRNA export is CRM1 dependent and requires the 4E-SE and the mRNA export factor LRPPRC (Culjkovic et al., 2006; Topisirovic et al., 2009a).
Thus eIF4E can modulate gene expression at two levels: by exporting mRNAs to the cytoplasm increasing their concentration therein and by enhancing the translational efficiency of transcripts that are already in the cytoplasm. Not all transcripts are affected at both levels. Importantly, eIF4E requires its m7G cap binding function in order to act in either of these functions.
eIF4E activity is regulated by many proteins. One of the best-characterized regulators of eIF4E is eIF4E binding protein 1 (BP1) (Sonenberg et al., 1998; Gingras et al., 1999; Zimmer et al., 2000; Wendel et al., 2007). This protein uses a conserved eIF4E binding site to associate with eIF4E, and thereby precludes access of eIF4E to eIF4G and the rest of the translation machinery (Sonenberg et al., 1998). This binding site is defined as follows: YXXXXLPhi (where X is any residue and Phi is a hydrophobic residue). Studies suggest that BP1 increases cap affinity and thereby sequesters both eIF4E and the RNA in question from the translational machinery (von der Haar et al., 2004). Further, endogenous BP1 associates with eIF4E in both the nuclear and cytoplasmic compartments and thus likely modulates eIF4E activity at both the level of translation and mRNA export (Rong et al., 2008). Phosphorylation of 4E-BP1 leads to a reduction in its interaction with eIF4E and thereby, results in increased translational activity of eIF4E. 4E-BP1 phosphorylation is mTOR dependent (Proud, 2007). However, BP1-/- and BP1-/-BP2-/- mice do not develop cancers more readily than controls (Blackshear et al., 1997; Tsukiyama-Kohara et al., 2001; Banko et al., 2006; Le Bacquer et al., 2007), highlighting the importance of redundancy of regulators in the control of eIF4E.
The vast majority of other eIF4E regulators contain the YXXXXLPhi motif like eIF4G and the BPs. These regulators include a set of over 200 homeodomain proteins that contain this motif. Some of these members are negative regulators of eIF4E, such as PRH/Hex. PRH is a nuclear protein that impedes eIF4Es mRNA export function, and its overexpression leads to the cytoplasmic re-distribution of eIF4E (Topisirovic et al., 2003a; Topisirovic et al., 2003b). Other members of this group of homeodomain containing regulators include Emx2, Otx, Engrailed 2, Hox11, Bicoid and HoxA9 (Topisirovic et al., 2005a). HoxA9 can stimulate both the nuclear and cytoplasmic functions of eIF4E (Topisirovic et al., 2005b).
There is also a discrete class of eIF4E regulators that utilize a RING domain to impede eIF4E function. These regulators include the promyelocytic leukemia protein PML, and arenaviral Z proteins from LCMV and Lassa viruses (Lai et al., 2000; Cohen et al., 2001; Ardley et al., 2001). Binding of PML or the Z proteins to eIF4E reduces the affinity of eIF4E for the m7G cap by up to 100 fold (Nathan et al., 1997; Graff et al., 2003; Topisirovic et al., 2003a). PML is a mostly nuclear protein, and thus primarily inhibits the mRNA export activity of eIF4E (Cohen et al., 2001; Kentsis et al., 2001; Culjkovic et al., 2005; Culjkovic et al., 2006; Culjkovic et al., 2008).
In conclusion, the regulation of eIF4E activity is redundant and multi-factorial. There are tissue specific regulators such as the homeodomain proteins and more ubiquitous regulators such as PML and 4E-BP1. Redundancy of regulators is seen for both the nuclear and cytoplasmic arms of eIF4E activity.


By analysis of expressed sequence tag sequences, two additional eIF4E-family members in mammals named eIF4E-2 (also known as 4EHP, 4E-LP) and eIF4E-3 were identified (Joshi et al., 2004). They differ in their structural signatures, functional characteristics and expression pattern from eIF4E (eIF4E-1). Like eIF4E-1, eIF4E-2 is expressed in all tissues, with highest levels in the testis, while eIF4E-3 is detectable only in muscles, spleen and lung. Unlike eIF4E-1, eIF4E-2 and eIF4E-3 are not able to rescue the growth of S. cerevisiae lacking a functional EIF4E gene. While both, eIF4E-2 and eIF4E-3 can bind the cap in vitro, eIF4E-2 and eIF4E-3 differ from eIF4E-1 and between each-other in their affinities to 4E-BPs and eIF4G. It is proposed that each eIF4E-family member fills a specialized role in the regulation of recruitment of mRNAs to ribosomes through differences in their ability to bind the cap and/or to interact with eIF4G and 4E-BPs.





Genome wide linkage studies in autism patients have shown linkage to the region containing the EIF4E locus on chromosome 4q (Yonan et al., 2003; Schellenberg et al., 2006). Recently, de novo chromosome translocation between 4q and 5q was reported in a boy with classic autism, and a breakpoint site was mapped within a proposed alternative transcript of eIF4E (Neves-Pereira et al., 2009). In the same study, screening of 120 autism families, two unrelated families were found, where in each case both autistic siblings and one of the parents harbored the same single nucleotide insertion at position -25 in the basal element of the EIF4E promoter. EMSA assays and reporter gene studies show that this mutation enhances EIF4E promoter activity by two fold.

Implicated in

Entity name
Various cancers
eIF4E is overexpressed in many epithelial cell cancers, including breast (Kerekatte et al., 1995; Li et al., 1997; Li et al., 1998; Li et al., 2002; McClusky et al., 2005), colon (Rosenwald et al., 1999; Berkel et al., 2001), bladder (Dickinson et al., 1994; Bochner et al., 1995; Jaeger et al., 1995; Crew et al., 1996; Crew et al., 2000), cervix (Lee et al., 2005; Matthews-Greer et al., 2005), prostate (Graff et al., 2009), lung (Rosenwald et al., 2001; Seki et al., 2002; Jacobson et al., 2006) and squamous cell carcinoma of the head and neck (Nathan et al., 1997b; Franklin et al., 1999; Nathan et al., 1999a; Nathan et al., 1999b; Sorrells et al., 1999b; Nathan et al., 2000; Chandy et al., 2002; Nathan et al., 2002). Some studies report that eIF4E is overexpressed in almost 100% of tumors of the breast, head and neck, and colon (Kerekatte et al., 1995; Nathan et al., 1999a; Nathan et al., 1999b). Several retrospective studies indicate that eIF4E overexpression is correlated with poor prognosis.
It has been demonstrated that eIF4E overexpression is associated with eIF4E gene amplification in both HNSCC and in breast carcinomas (Sorrells et al., 1998; Sorrells et al., 1999a; Sorrells et al., 1999b; Haydon et al., 2000). An increased level of eIF4E gene amplification was observed in invasive carcinomas of the head and neck as compared to benign tumors. Benign tumors only had moderate evidence for gene amplification, while malignant tumors had a 4-15 fold level of amplification. These studies suggest that progression to the malignant phenotype paralleled eIF4E gene amplification and overexpression (Haydon et al., 2000). Also, there was a progressive increase in the degree of eIF4E gene amplification and protein expression when comparisons were made among samples from tumor free margins of resected carcinoma specimens, tumor free regions adjacent to tumor core and tumor core samples (Sorrells et al., 1998). This suggests that molecular events such as eIF4E gene amplification may precede cellular morphological changes, and that surgical margins which appear tumor free microscopically, may have elevated eIF4E protein levels. Thus, eIF4E levels could be used as a marker for prediction of early recurrence. It has been postulated that somewhere in the multi-step pathway of carcinogenesis, elevation of eIF4E is a necessary event in progression of most solid tumors, and that eIF4E does not only reflect the proliferative status of cells but also their malignant properties (Anthony et al., 1996; Nathan et al., 1997b).
Entity name
Breast cancer
eIF4E overexpression was detected at a range of 3-30 fold in breast carcinomas compared to normal breast tissue (Kerekatte et al., 1995; Li et al., 1997), and eIF4E levels were significantly increased in vascularized malignant ductules of invasive carcinomas (Nathan et al., 1997a). Breast cancer patients with high eIF4E expression (>7 fold relative to normal) experienced a statistically significant poorer clinical outcome with a higher risk for recurrence and cancer related death (Li et al., 1998). There were no correlation between node stage and the degree of 4E overexpression (McClusky et al., 2005).
Entity name
Prostate cancer
78% of prostate cancer samples in tissue microarray showed elevated eIF4E (Yang et al., 2007). eIF4E was found to be more than 3 times increased at protein level in prostate cancer, and also correlated with worse prognosis (Graff et al., 2008).
Entity name
Head and neck squamous cell carcinoma (HNSCC)
In the HNSCC, eIF4E levels were found 3 to 22 fold elevated relative to normal controls (Nathan et al., 1997b; Nathan et al., 1999a; Nathan et al., 1999b; Nathan et al., 2000; Nathan et al., 2002). High eIF4E levels in surgical margins are also predictive of increased risk of recurrence in HNSCC (Nathan et al., 1997b; Nathan et al., 1999a; Nathan et al., 2000; Nathan et al., 2002). Overexpression of eIF4E in >5% of the basal layer of histologically tumor-free surgical margins of HNSCC patients predicted a significantly increased risk of recurrence (Nathan et al., 1999a). This prediction is important for patient outcome, as most HNSCC patients will succumb due to local recurrence (Nathan et al., 1997b; Nathan et al., 2000; Nathan et al., 2002).
In acute myeloid leukemia (AML), elevated eIF4E levels are characteristic of the poor prognosis in M4 and M5 AML subtypes (Topisirovic et al., 2003b). Ribavirin, a competitive inhibitor of the cap was used in the clinical trial to target eIF4E in poor prognosis leukemia patients and led to striking clinical responses including complete and partial remissions (Assouline et al., 2009). This was the first time eIF4E was directly targeted in humans.
Entity name
Non-Hodgkin lymphoma
Increased level of eIF4E was observed in non-Hodgkins lymphomas and not in benign lesions (Wang et al., 1999; Mossafa et al., 2006). Here, eIF4E levels correlated with the aggressiveness of these lesions (Wang et al., 1999; Mossafa et al., 2006). Recently it was reported that eIF4E is overexpressed in 40% of mantle cell lymphoma (Inamdar et al., 2009) and that eIF4E is an independent predictor of clinical outcome in MCL patients treated with the R-hyper CVAD regimen.
Entity name
By immunohistochemical analysis it was shown that eIF4E is elevated in 69% of nodular sclerosis Hodgkin lymphomas (HL), 75% mixed cellularity HL, and 91% lymphocyte predominant HL ID: 2157> (Rosenwald et al., 2008).
Entity name
Colorectal adenomas and carcinomas
eIF4E protein was found to be 2-6 times increased in tumor samples, and even more in the tumor margins (Rosenwald et al., 1999).
Entity name
Pancreatic ductal adenocarcinoma
85% of pancreatic ductal adenocarcinoma samples showed high eIF4E staining in cancer tissue. There was no significant correlation between eIF4E expression and age, gender, histopathological grading, lymphatic invasion or lymph node metastasis. Also, there were no significant differences between the high eIF4E expressing group and either the low or moderate eIF4E expressing groups (Mishra et al., 2009).
Entity name
Lung carcinomas
In bronchioalveolar carcinoma, estimated by immunohistochemistry, eIF4E was found to be 3-8 times elevated (Rosenwald et al., 2001). Analysis of atypical adenomatous hyperplasia and peripheral lung adenocarcinoma samples showed 3.4-7.4 fold of eIF4E protein elevation (Seki et al., 2002). In Another study, 54% of lung adenocarcinoma samples showed high eIF4E expression by immunostaining. Analyses of mRNA and protein from tumor tissues showed 6-10x elevation compared to surrounding normal tissues (Wang et al., 2009). Elevated eIF4E immunostaining was found in 81% of non small cell lung cancer (NSCLC) samples from tissue microarray (Yang et al., 2007).
Another study reported that 91% of NSCLC samples had stronger eIF4E staining than adjacent normal bronchial mucosa. According to subtypes, eIF4E was positive in 88% of adenocarcinoma and 100% cases of squamous cell carcinomas (Khoury et al., 2009). Patients with eIF4E had more than 3 times risk of death than those with negative eIF4E (Khoury et al., 2009).
Entity name
Bladder cancers
eIF4E was found 4-10 times increased at protein and mRNA levels (Crew et al., 2000).
Entity name
Brain tumors (oligodendroglial, astrocytomas and meningiomas)
In brain tumors, eIF4E was more than 3 times increased at protein level, being highest in oligodendroglial tumors (Tejada et al., 2009).
Entity name
Glioblastoma multiforme
In tissue microarray 48% of samples showed elevated eIF4E immunostaining (Yang et al., 2007).
Entity name
Thyroid carcinoma
Elevated immunostaining especially in aggressive types (Wang et al., 2001).
Entity name
Cervical cancers
In cervical cancer, eIF4E was found 2-4 fold elevated by immunohistochemical staining (Matthews-Greer et al., 2005). Another study showed 7 fold increased mRNA levels of eIF4E (Van Trappen et al., 2002). Strong immunostaining of eIF4E was found in 21.1% of low-grade cervical intraepithelial neoplasias (CIN) and in 89.5% of high grade CIN, and none in low grade CINs. In another study, 100% of invasive squamous cell carcinoma showed strong eIF4E immunostaining, while mRNA was 2-4 times elevated comparing to normal samples (Lee et al., 2005). No significant difference in eIF4E expression was found between HPV+ and HPV- negative, single or double infected samples (Matthews-Greer et al., 2005).
Entity name
Ovarian cancers
In tissue microarray 50% of ovarian cancer samples showed elevated eIF4E (Yang et al., 2007). Also, p-eIF4E was increased in 56% analyzed samples (Noske et al., 2008).


Pubmed IDLast YearTitleAuthors
35504381987mRNA cap-binding protein: cloning of the gene encoding protein synthesis initiation factor eIF-4E from Saccharomyces cerevisiae.Altmann M et al
26638511989A mammalian translation initiation factor can substitute for its yeast homologue in vivo.Altmann M et al
86316041996Overexpression of the proto-oncogene/translation factor 4E in breast-carcinoma cell lines.Anthony B et al
112788162001Features of the parkin/ariadne-like ubiquitin ligase, HHARI, that regulate its interaction with the ubiquitin-conjugating enzyme, Ubch7.Ardley HC et al
194338562009Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.Assouline S et al
164954432006Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression.Banko JL et al
114019172001Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon.Berkel HJ et al
93954871997Disruption of the gene encoding the mitogen-regulated translational modulator PHAS-I in mice.Blackshear PJ et al
75632031995Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis.Bochner BH et al
119565372002Expression of the proto-oncogene eIF4E in inflammation of the oral cavity.Chandy B et al
115003812001PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA.Cohen N et al
106389842000Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression.Crew JP et al
88424941996Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.Crew JP et al
183910712008The eIF4E RNA regulon promotes the Akt signaling pathway.Culjkovic B et al
102169441999eIF4E expression in tumors: its possible role in progression of malignancies.De Benedetti A et al
75301311994Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas.Dickinson AJ et al
106533551999Dynamic and tissue-specific expression of eIF4E during zebrafish embryogenesis.Fahrenkrug SC et al
76655841995Serine 209, not serine 53, is the major site of phosphorylation in initiation factor eIF-4E in serum-treated Chinese hamster ovary cells.Flynn A et al
100372841999Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers.Franklin S et al
94685201998Cloning and characterization of human eIF4E genes.Gao M et al
103641591999Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.Gingras AC et al
182454602008Targeting the eukaryotic translation initiation factor 4E for cancer therapy.Graff JR et al
127416842003Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs.Graff JR et al
146755382003Ribosome loading onto the mRNA cap is driven by conformational coupling between eIF4G and eIF4E.Gross JD et al
108700642000Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck.Haydon MS et al
94194251997Pim-1 protein expression is regulated by its 5'-untranslated region and translation initiation factor elF-4E.Hoover DS et al
114236162001Coupled transcription and translation within nuclei of mammalian cells.Iborra FJ et al
197080312009Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.Inamdar KV et al
166187492006Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo.Jacobson BA et al
75398691995Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer.Jaeger TM et al
87566331996An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc.Jones RM et al
77823231995Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209.Joshi B et al
151531092004Characterization of mammalian eIF4E-family members.Joshi B et al
121881922002Yeast "knockout-and-rescue" system for identification of eIF4E-family members possessing eIF4E-activity.Joshi B et al
115759182001The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E.Kentsis A et al
76652441995The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas.Kerekatte V et al
86315931996Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis.Kevil CG et al
192893742009Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer.Khoury T et al
107638192000The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA.Lai HK et al
172735562007Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2.Le Bacquer O et al
162602732005eIF-4E expression is associated with histopathologic grades in cervical neoplasia.Lee JW et al
13840581992A fraction of the mRNA 5' cap-binding protein, eukaryotic initiation factor 4E, localizes to the nucleus.Lejbkowicz F et al
119812202002Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome.Li BD et al
91915271997Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma.Li BD et al
96056671998Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression.Li BD et al
160247822005hnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation.Lynch M et al
113115502001Transcriptional regulation of the rat eIF4E gene in cardiac muscle cells: the role of specific elements in the promoter region.Makhlouf AA et al
14003631992Regulation of translation initiation factor gene expression during human T cell activation.Mao X et al
103943591999Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G.Marcotrigiano J et al
93029991997Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein.Matsuo H et al
162806682005eIF4E as a marker for cervical neoplasia.Matthews-Greer J et al
161928192005A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer.McClusky DR et al
93214021997Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain.McCoy M et al
80526401994Chromatographic resolution of in vivo phosphorylated and nonphosphorylated eukaryotic translation initiation factor eIF-4E: increased cap affinity of the phosphorylated form.Minich WB et al
193603362009Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.Mishra R et al
170650022006Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis.Mossafa H et al
167205732006Ubiquitination and proteasome-dependent degradation of human eukaryotic translation initiation factor 4E.Murata T et al
124613302002Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.Nathan CO et al
92855631997Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas.Nathan CO et al
104438291999Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis.Nathan CO et al
92473111997Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer.Nathan CO et al
109100742000Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications.Nathan CO et al
195562532009Deregulation of EIF4E: a novel mechanism for autism.Neves-Pereira M et al
190207222008Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis.Noske A et al
158788682005Eukaryotic translation initiation factor 4E is a cellular target for toxicity and death due to exposure to cadmium chloride.Othumpangat S et al
111304642000The structure and function of initiation factors in eukaryotic protein synthesis.Pestova TV et al
173760312007Signalling to translation: how signal transduction pathways control the protein synthetic machinery.Proud CG et al
104068111999Repressor binding to a dorsal regulatory site traps human eIF4E in a high cap-affinity state.Ptushkina M et al
98780691999Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E.Pyronnet S et al
82347841993Mechanism of action and regulation of protein synthesis initiation factor 4E: effects on mRNA discrimination, cellular growth rate, and oncogenesis.Rhoads RE et al
147018182004Two zebrafish eIF4E family members are differentially expressed and functionally divergent.Robalino J et al
185155452008Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs.Rong L et al
182342812008Expression of the translation initiation factors eIF-4E and eIF-2* is frequently increased in neoplastic cells of Hodgkin lymphoma.Rosenwald IB et al
85777151996Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E.Rousseau D et al
168808252006Evidence for multiple loci from a genome scan of autism kindreds.Schellenberg GD et al
117231112002Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA.Scheper GC et al
123746712002Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung.Seki N et al
95618521998The mRNA 5' cap-binding protein eIF4E and control of cell growth.Sonenberg N et al
100772001999Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers.Sorrells DL Jr et al
103838351999Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor.Sorrells DL et al
119636522002The emerging roles of translation factor eIF4E in the nucleus.Strudwick S et al
191884862009Eukaryotic initiation factors (eIF) 2alpha and 4E expression, localization, and phosphorylation in brain tumors.Tejada S et al
118791792002Crystal structures of 7-methylguanosine 5'-triphosphate (m(7)GTP)- and P(1)-7-methylguanosine-P(3)-adenosine-5',5'-triphosphate (m(7)GpppA)-bound human full-length eukaryotic initiation factor 4E: biological importance of the C-terminal flexible region.Tomoo K et al
191145522009Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer.Topisirovic I et al
115904362001Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1.Tsukiyama-Kohara K et al
121895532002A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer.Van Trappen PO et al
86361341996Mutants of eukaryotic initiation factor eIF-4E with altered mRNA cap binding specificity reprogram mRNA selection by ribosomes in Saccharomyces cerevisiae.Vasilescu S et al
170360472006Cap-free structure of eIF4E suggests a basis for conformational regulation by its ligands.Volpon L et al
126415662003Increased levels of the translation initiation factor eIF4E in differentiating epithelial lung tumor cell lines.Walsh D et al
192613482009Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma.Wang R et al
121864962001Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with the progression of thyroid carcinoma.Wang S et al
103938561999Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas.Wang S et al
95452601998The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways.Wang X et al
100228741999Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo.Waskiewicz AJ et al
180556952007Dissecting eIF4E action in tumorigenesis.Wendel HG et al
93966311997Fluorescence and NMR studies of intramolecular stacking of mRNA cap-analogues.Wieczorek Z et al
202245762010Sumoylation of eIF4E activates mRNA translation.Xu X et al
172031622007Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray.Yang SX et al
136805282003A genomewide screen of 345 families for autism-susceptibility loci.Yonan AL et al
161126472005Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53.Zhu N et al
109280422000Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis.Zimmer SG et al
151640082004The mRNA cap-binding protein eIF4E in post-transcriptional gene expression.von der Haar T et al

Other Information

Locus ID:

NCBI: 1977
MIM: 133440
HGNC: 3287
Ensembl: ENSG00000151247


dbSNP: 1977
ClinVar: 1977
TCGA: ENSG00000151247


Gene IDTranscript IDUniprot

Expression (GTEx)



PathwaySourceExternal ID
mTOR signaling pathwayKEGGko04150
Insulin signaling pathwayKEGGko04910
mTOR signaling pathwayKEGGhsa04150
Insulin signaling pathwayKEGGhsa04910
RNA transportKEGGko03013
RNA transportKEGGhsa03013
eIF4F complexKEGGhsa_M00428
PI3K-Akt signaling pathwayKEGGhsa04151
PI3K-Akt signaling pathwayKEGGko04151
HIF-1 signaling pathwayKEGGhsa04066
eIF4F complexKEGGM00428
Metabolism of proteinsREACTOMER-HSA-392499
Eukaryotic Translation InitiationREACTOMER-HSA-72613
Cap-dependent Translation InitiationREACTOMER-HSA-72737
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43SREACTOMER-HSA-72662
Translation initiation complex formationREACTOMER-HSA-72649
Ribosomal scanning and start codon recognitionREACTOMER-HSA-72702
GTP hydrolysis and joining of the 60S ribosomal subunitREACTOMER-HSA-72706
L13a-mediated translational silencing of Ceruloplasmin expressionREACTOMER-HSA-156827
Immune SystemREACTOMER-HSA-168256
Cytokine Signaling in Immune systemREACTOMER-HSA-1280215
Interferon SignalingREACTOMER-HSA-913531
Antiviral mechanism by IFN-stimulated genesREACTOMER-HSA-1169410
ISG15 antiviral mechanismREACTOMER-HSA-1169408
Signal TransductionREACTOMER-HSA-162582
Signaling by Insulin receptorREACTOMER-HSA-74752
Insulin receptor signalling cascadeREACTOMER-HSA-74751
IRS-mediated signallingREACTOMER-HSA-112399
PI3K CascadeREACTOMER-HSA-109704
PKB-mediated eventsREACTOMER-HSA-109703
mTOR signallingREACTOMER-HSA-165159
mTORC1-mediated signallingREACTOMER-HSA-166208
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)REACTOMER-HSA-2404192
IGF1R signaling cascadeREACTOMER-HSA-2428924
IRS-related events triggered by IGF1RREACTOMER-HSA-2428928
Gene ExpressionREACTOMER-HSA-74160
Processing of Capped Intron-Containing Pre-mRNAREACTOMER-HSA-72203
Transport of Mature Transcript to CytoplasmREACTOMER-HSA-72202
Transport of Mature mRNAs Derived from Intronless TranscriptsREACTOMER-HSA-159234
Transport of the SLBP Dependant Mature mRNAREACTOMER-HSA-159230
Transport of the SLBP independent Mature mRNAREACTOMER-HSA-159227
Transport of Mature mRNA Derived from an Intronless TranscriptREACTOMER-HSA-159231
Deadenylation-dependent mRNA decayREACTOMER-HSA-429914
Deadenylation of mRNAREACTOMER-HSA-429947
Longevity regulating pathwayKEGGhsa04211
EGFR tyrosine kinase inhibitor resistanceKEGGko01521
EGFR tyrosine kinase inhibitor resistanceKEGGhsa01521

Protein levels (Protein atlas)

Not detected


Pubmed IDYearTitleCitations
158408192005A role for eIF4E and eIF4E-transporter in targeting mRNPs to mammalian processing bodies.159
177862462007Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.149
175244642007An mRNA m7G cap binding-like motif within human Ago2 represses translation.146
255339572015Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch.140
218761522011PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.107
170748852006eIF4E is a central node of an RNA regulon that governs cellular proliferation.97
228721502012DEAD-box protein DDX3 associates with eIF4F to promote translation of selected mRNAs.88
122392922002Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1.77
176679412008Candidate tumor suppressor DDX3 RNA helicase specifically represses cap-dependent translation by acting as an eIF4E inhibitory protein.75
146455122003Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis.71


Katherine LB Borden ; Biljana Culjkovic-Kraljacic ; Laurent Volpon

EIF4E (eukaryotic translation initiation factor 4E)

Atlas Genet Cytogenet Oncol Haematol. 2010-05-01

Online version: http://atlasgeneticsoncology.org/gene/40431/eif4e-(eukaryotic-translation-initiation-factor-4e)